Tihana Bicanic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3677261/publications.pdf

Version: 2024-02-01

61	6,158	94269	138251
papers	citations	37 h-index	58 g-index

69	69	69	4973
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
2	Tackling the emerging threat of antifungal resistance to human health. Nature Reviews Microbiology, 2022, 20, 557-571.	13.6	311
3	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	2.3	24
4	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. Journal of Infection, 2021, 82, 90-97.	1.7	12
5	AIDS-Related Mycoses. , 2021, , 763-780.		0
6	Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality. ACS Infectious Diseases, 2021, 7, 377-389.	1.8	17
7	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2021, 8, ofab066.	0.4	6
8	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	4.6	80
9	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	2.1	39
10	Cryptococcal meningoencephalitis: time for action. Lancet Infectious Diseases, The, 2021, 21, e259-e271.	4.6	29
11	Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 759408.	1.8	31
12	Invasive candidiasis in critical care: challenges and future directions. Intensive Care Medicine, 2020, 46, 2001-2014.	3.9	73
13	Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. Journal of Infection, 2020, 81, e55-e57.	1.7	54
14	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2002554.	3.1	98
15	Late presentation of amoebic liver abscess. Lancet Infectious Diseases, The, 2020, 20, 259.	4.6	0
16	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. Open Forum Infectious Diseases, 2020, 7, ofaa489.	0.4	12
17	Case Report: Visceral Leishmaniasis Falsely Diagnosed as Q Fever. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1927-1929.	0.6	2
18	Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature. Journal of Fungi (Basel, Switzerland), 2020, 6, 385.	1.5	7

#	Article	IF	Citations
19	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. MBio, 2019, 10, .	1.8	44
20	Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010â€“16. Journal of Antimicrobial Chemotherapy, 2019, 74, 234-241.	1.3	27
21	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	4.6	63
22	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. Journal of Clinical Investigation, 2019, 129, 999-1014.	3.9	112
23	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. New England Journal of Medicine, 2018, 378, 1004-1017.	13.9	296
24	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. MBio, 2018, 9, .	1.8	5
25	Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. The Cochrane Library, 2018, 2018, CD009012.	1.5	23
26	The Cryptococcus neoformans Titan cell is an inducible and regulated morphotype underlying pathogenesis. PLoS Pathogens, 2018, 14, e1006978.	2.1	137
27	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. G3: Genes, Genomes, Genetics, 2017, 7, 1165-1176.	0.8	79
28	AIDS-Related Mycoses: Current Progress in the Field and Future Priorities. Trends in Microbiology, 2017, 25, 428-430.	3.5	16
29	Tracing Genetic Exchange and Biogeography of Cryptococcus neoformans var. grubii at the Global Population Level. Genetics, 2017, 207, 327-346.	1.2	105
30	Genomic epidemiology of Cryptococcus yeasts identifies adaptation to environmental niches underpinning infection across an African <scp>HIV</scp>/<scp>AIDS</scp> cohort. Molecular Ecology, 2017, 26, 1991-2005.	2.0	59
31	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	1.3	47
32	Liposomal Amphotericin B (AmBisomeÂ®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs, 2016, 76, 485-500.	4.9	332
33	Cryptococcus: from environmental saprophyte to global pathogen. Nature Reviews Microbiology, 2016, 14, 106-117.	13.6	387
34	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0003847.	1.3	94
35	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. PLoS Pathogens, 2015, 11, e1004754.	2.1	117
36	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2015, 59, 7224-7231.	1.4	99

#	Article	IF	Citations
37	Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genetics and Biology, 2015, 78, 49-54.	0.9	194
38	The Cryptococcus neoformans Transcriptome at the Site of Human Meningitis. MBio, 2014, 5, e01087-13.	1.8	113
39	Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2014, 209, 74-82.	1.9	90
40	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clinical Infectious Diseases, 2014, 58, 736-745.	2.9	299
41	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 493-500.	2.9	10
42	Therapy of AIDS-Related Cryptococcal Meningitis. Current Treatment Options in Infectious Diseases, 2014, 6, 294-308.	0.8	2
43	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. Journal of Clinical Investigation, 2014, 124, 2000-2008.	3.9	130
44	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infectious Diseases, The, 2013, 13, 629-637.	4.6	151
45	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. Journal of Infection, 2013, 66, 75-79.	1.7	27
46	Adjunctive interferon-Î³ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. Aids, 2012, 26, 1105-1113.	1.0	238
47	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2012, 54, 121-128.	2.9	127
48	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. Journal of Infection, 2011, 63, 484-486.	1.7	15
49	Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics, 2011, 12, 526.	1.2	62
50	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. Clinical Infectious Diseases, 2010, 51, 986-987.	2.9	7
51	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIVâ€Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. Clinical Infectious Diseases, 2009, 49, 702-709.	2.9	201
52	Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 130-134.	0.9	162
53	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids, 2009, 23, 1182-1183.	1.0	83
54	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. Aids, 2009, 23, 701-706.	1.0	168

#	Article	IF	Citations
55	HighâEDose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIVâEInfected Patients: A Randomized Trial. Clinical Infectious Diseases, 2008, 47, 123-130.	2.9	238
56	Reply to Pasqualotto. Clinical Infectious Diseases, 2008, 47, 1110-1111.	2.9	2
57	Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole. Clinical Infectious Diseases, 2007, 45, 76-80.	2.9	261
58	Symptomatic Relapse of HIVâEAssociated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution. Clinical Infectious Diseases, 2006, 43, 1069-1073.	2.9	210
59	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. Journal of Infection, 2005, 51, e221-e224.	1.7	56
60	Cryptococcal meningitis. British Medical Bulletin, 2004, 72, 99-118.	2.7	286
61	Evaluation of perturbed iron-homeostasis in a prospective cohort of patients with COVID-19. Wellcome Open Research, 0, 7, 173.	0.9	4